webcast _ 2nd DAAs

BM_DAAs2nd International Workshop on Optimal Use of DAAs in Advanced Liver Disease and

8 April 2014, London, United Kingdom

Webcasts have been made possible through an unrestricted educational grant from Gilead Sciences.


Invited Lectures


Bourliere, Mark_2013
arc Bourlière, MD
Experience with Boceprevir and Telaprevir in Cirrhosis

 Afdhal, Nezam
Nezam Afdhal, MD
Experience with Sofosbuvir, Simeprevir, and Others in Cirrhosis
 Terrault, Norah 2012
Norah Terrault, MD, MPH
Experience with Boceprevir and Telaprevir in Liver Transplant
 Forns, Xavier 2011
Xavier Forns, MD, MPH
Experience with Sofosbuvir in Liver Transplant

Round Table Discussions

 Use of DAAs in Cirrhosis or in Patients on the Waiting List
Jean-Michiel Pawlotsky, MD, PhD  //  Robert S. Brown, MD, MPH  //  Joost Drenth, MD, PHD  //  Peter Ferenci, MD  //  Didier Samuel, MD, PhD
 Use of DAAs after Liver Transplantation
Marina Berenguer, MD  //  Federico Villamil, MD  //  Russell Wiesner, MD  //  Audrey Coilly, MD  //  John O’Grady, MD

Clinical Case presentations

 Pre-Transplant Patients:
Marina Berenguer, MD
Joost Drenth, MD, PHD
Xavier Forns, MD, MPH
Gregory T. Everson, MD
 Post-Transplant patients:
Russell Wiesner, MD
Peter Ferenci, MD
Rajender Reddy, MD
Eugene Schiff, MD
Paul Kwo, MD